[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plaque-type-psorisis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plaque-type-psorisis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100634916","clinical-study-on-the-medical-devices-proxera-psomed-20-and-proxera-psomed-40-for-the-treatment-of-plaque-psoriasis-and-non-pustular-palmoplantar-psoriasis-100634916",false,"NCT07545902","Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis","Evaluation of the Efficacy and Safety of the Medical Device PROXERA PSOMED 20 in Reducing Psoriatic Plaques and of the Medical Device PROXERA PSOMED 40 in Reducing Non-pustulous Palmoplantar Psoriasis Flaw in Patients With Plaque Psoriasis: a Sponsored, Interventional, Single-center, Randomized, Single-blind, Intra-patient Controlled Study (PASI)","PASI","Inclusion Criteria:\n\nPROXERA PSOMED 20 - normalizing cream, 20% urea\n\n* Diagnosis of plaque psoriasis (not palmoplantar) for at least 1 year PROXERA PSOMED 40 - intensive exfoliating gel, 40% urea\n* Diagnosis of non-pustular palmoplantar psoriasis for at least 1 year\n\nCommon inclusion criteria:\n\n* Age 18-65 years\n* \"Mild\" psoriasis severity according to:\n* Psoriasis Area Severity Index (PASI) \\\u003C10\n* Dermatologic Life Quality Index (DLQI) \\\u003C10\n* Body Surface Area (BSA) \\\u003C10\n\nExclusion Criteria:\n\n* Product intolerance\n* Concomitant therapy with systemic immunomodulatory drugs (e.g., methotrexate, cyclosporine, apremilast)\n* Concomitant therapy with biologic drugs such as anti-TNFα, anti-IL17, or anti-IL23.\n* Concomitant topical therapy with topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), vitamin D analogues, and combinations.\n* Pregnant or breastfeeding women","ALL","18 Years","65 Years",{"count":21,"type":22},35,"ESTIMATED","INTERVENTIONAL",[25],"NA","This single-center interventional study was designed to evaluate the efficacy and safety of two CE-marked topical medical devices: PROXERA PSOMED 20 is being studied in participants with non-palmoplantar plaque psoriasis, while PROXERA PSOMED 40 is being studied in participants with non-pustular palmoplantar psoriasis.\n\nThe study aims to determine whether treating a target area with the assigned medical device leads to greater clinical improvement compared to the untreated contralateral control area in the same participant. For PROXERA PSOMED 20, the primary assessment is performed after 4 weeks of treatment. For PROXERA PSOMED 40, the primary assessment is performed after 8 weeks of treatment.\n\nSecondary objectives include the assessment of safety, local tolerability, overall psoriasis progress, its impact on quality of life, and additional parameters of local disease activity at the target areas. Participants will apply the assigned study device once daily to the selected target area, undergo clinical assessments at scheduled visits, and provide safety and tolerability information throughout the study.",[28,29],"Plaque Type Psorisis","Non-pustular Palmoplantar Psoriasis",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Plaque Psoriasis","Non-Pustular Palmoplantar Psoriasis","PROXERA PSOMED 20","PROXERA PSOMED 40","Urea","Topical Medical Device","Intra-patient Controlled Study","Randomized Study","Single-Blind Study","Psoriasis Area Severity Index","Target Lesion Score","Dermatologic Life Quality Index","modified Palmoplantar Psoriasis Area Severity Index","Trans Epidermal Water Loss","dermato-capillaroscopy","NOT_YET_RECRUITING","2026-04-16",{"date":49,"type":50},"2026-04-22","ACTUAL",{"date":52,"type":22},"2026-04-28",{"date":54,"type":22},"2026-10-20",{"name":56,"class":57},"ICIM International S.r.l.","INDUSTRY",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":58},"100624527","phase-2-acupuncture-with-chinese-herbal-cream-compare-with-acupuncture-with-calcipotriol-in-plaque-psoriasis-100624527","NCT07410793","Acupuncture With Chinese Herbal Cream Compare With Acupuncture With Calcipotriol in Plaque Psoriasis.","Comparative Efficacy of Acupuncture Combined With Chinese Herbal Cream and Acupuncture Combined With Calcipotriol for Plaque Psoriasis.","Inclusion Criteria:\n\n* Plaque psoriasis on skin, scalp, or nails\n* Not receive any psoriasis treatment at least 4 weeks prior to the study\n* ≤10% body surface area (BSA), PASI≤10, DLQI≤10\n\nExclusion Criteria:\n\n* Pregnancy and lactation\n* Other type of psoriasis i.e. Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis\n* Uncontrollable diseases i.e. CVS, liver, kidney, cancer\n* Using anticoagulants i.e. Aspirin, Warfarin, Clopidogrel, Dabigatran, Riavaraxaban, Apixaban, Heparin\n* Treated with psoriasis biologic agents in the past 6 months\n* Needle phobia\n* Receiving immunosuppresive agents i.e. systemic corticosteroid, NSAIDs, chemotherapeutic agents\n* Participating in other clinical study",{"count":67,"type":22},28,[69],"PHASE2","Clinical trial which compares 2 treatment methods (1) Acupunture with a Chinese Herbal Cream and (2) Acupuncture with the standard treatment \"calcipotriol\" for patients with plaque psoriasis.",[28],[73,74,75,76],"plaque psoriasis","acupuncture","chinese herbal cream","calcipotriol","RECRUITING","2026-02-08",{"date":80,"type":50},"2026-02-13",{"date":82,"type":50},"2026-02-09",{"date":84,"type":22},"2027-02-08",{"name":86,"class":87},"Mae Fah Luang University","OTHER"]